Department of Gynecology and Obstetrics, National Center of Tumor Diseases, University Hospital of Heidelberg, Voßstraße 9, 69115 Heidelberg, Germany.
Cancer Immunol Immunother. 2011 Sep;60(9):1221-5. doi: 10.1007/s00262-011-1062-y. Epub 2011 Jun 17.
Breast cancer and associated diabetes mellitus have gained raising interest as an elevated risk of breast cancer prognosis resulting in increased mortality in diabetic patients. In this context, the long-acting insulin analog glargine and other antidiabetics have been discussed to promote tumorigenesis. In contrast, the biguanide class oral antidiabetic metformin has been shown capable of enhancing cell cycle arrest and inducing apoptosis as well as reducing growth factor signaling. Consequently, several studies are underway to evaluate a possible role of metformin in breast cancer treatment. Although mechanisms involved are not definitely clear yet, here, we discuss metformin's anticancer effects including the potential impact of the immune system.
乳腺癌和相关的糖尿病已经引起了越来越多的关注，因为糖尿病患者的乳腺癌预后风险增加导致死亡率上升。在这种情况下，长效胰岛素类似物甘精胰岛素和其他抗糖尿病药物已被讨论用于促进肿瘤发生。相比之下，双胍类口服抗糖尿病药物二甲双胍已被证明能够促进细胞周期停滞和诱导细胞凋亡，并减少生长因子信号。因此，正在进行几项研究来评估二甲双胍在乳腺癌治疗中的可能作用。尽管涉及的机制尚不完全清楚，但在这里，我们讨论了二甲双胍的抗癌作用，包括免疫系统的潜在影响。
